BR112019018966A2 - analógicos da deutetrabenazina, sua preparação e uso - Google Patents
analógicos da deutetrabenazina, sua preparação e uso Download PDFInfo
- Publication number
- BR112019018966A2 BR112019018966A2 BR112019018966-1A BR112019018966A BR112019018966A2 BR 112019018966 A2 BR112019018966 A2 BR 112019018966A2 BR 112019018966 A BR112019018966 A BR 112019018966A BR 112019018966 A2 BR112019018966 A2 BR 112019018966A2
- Authority
- BR
- Brazil
- Prior art keywords
- deutetrabenazine
- compound
- concentration
- area
- pharmaceutical composition
- Prior art date
Links
- 0 CC(C)CC(C=*1C(C2)c3cc(*=C)c(*)cc3CC1)C2=* Chemical compound CC(C)CC(C=*1C(C2)c3cc(*=C)c(*)cc3CC1)C2=* 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Pens And Brushes (AREA)
- Machine Translation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471484P | 2017-03-15 | 2017-03-15 | |
| US62/471,484 | 2017-03-15 | ||
| PCT/US2018/022562 WO2018170214A1 (en) | 2017-03-15 | 2018-03-15 | Analogs of deutetrabenazine, their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019018966A2 true BR112019018966A2 (pt) | 2020-04-22 |
Family
ID=61873991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019018966-1A BR112019018966A2 (pt) | 2017-03-15 | 2018-03-15 | analógicos da deutetrabenazina, sua preparação e uso |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11813232B2 (enExample) |
| EP (1) | EP3596077A1 (enExample) |
| JP (3) | JP7608050B2 (enExample) |
| KR (2) | KR20200003791A (enExample) |
| CN (1) | CN110709398A (enExample) |
| AR (1) | AR111182A1 (enExample) |
| AU (2) | AU2018236336B2 (enExample) |
| BR (1) | BR112019018966A2 (enExample) |
| CA (1) | CA3056612A1 (enExample) |
| CL (1) | CL2019002629A1 (enExample) |
| CO (1) | CO2019011271A2 (enExample) |
| EA (1) | EA201992168A1 (enExample) |
| IL (1) | IL269132A (enExample) |
| MX (1) | MX2019010913A (enExample) |
| PE (1) | PE20191819A1 (enExample) |
| SG (1) | SG11201908477QA (enExample) |
| TW (1) | TWI772382B (enExample) |
| UA (1) | UA127052C2 (enExample) |
| WO (1) | WO2018170214A1 (enExample) |
| ZA (1) | ZA201906326B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113395966A (zh) * | 2018-12-13 | 2021-09-14 | 奥斯佩克斯医药公司 | 用于治疗脑瘫中的运动障碍的方法 |
| WO2020165807A1 (en) * | 2019-02-14 | 2020-08-20 | Dr. Reddy's Laboratories Limited | Solid forms of deutetrabenazine and process for the preparation thereof |
| PE20230852A1 (es) * | 2020-06-10 | 2023-05-29 | Auspex Pharmaceuticals Inc | Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007317242B2 (en) | 2006-11-08 | 2013-08-01 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
| EP3345905B1 (en) | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| JP6362601B2 (ja) * | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| US9550780B2 (en) * | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2930744A1 (en) * | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| IL288712B2 (en) | 2015-03-06 | 2024-01-01 | Auspex Pharmaceuticals Inc | Methods for the treatment of abnormal involuntary movement disorders |
-
2018
- 2018-03-15 WO PCT/US2018/022562 patent/WO2018170214A1/en not_active Ceased
- 2018-03-15 CN CN201880018609.8A patent/CN110709398A/zh active Pending
- 2018-03-15 PE PE2019001871A patent/PE20191819A1/es unknown
- 2018-03-15 JP JP2019550774A patent/JP7608050B2/ja active Active
- 2018-03-15 UA UAA201910309A patent/UA127052C2/uk unknown
- 2018-03-15 AR ARP180100611A patent/AR111182A1/es unknown
- 2018-03-15 SG SG11201908477Q patent/SG11201908477QA/en unknown
- 2018-03-15 MX MX2019010913A patent/MX2019010913A/es unknown
- 2018-03-15 EP EP18715393.7A patent/EP3596077A1/en active Pending
- 2018-03-15 US US15/922,329 patent/US11813232B2/en active Active
- 2018-03-15 AU AU2018236336A patent/AU2018236336B2/en active Active
- 2018-03-15 KR KR1020197030354A patent/KR20200003791A/ko not_active Ceased
- 2018-03-15 TW TW107108832A patent/TWI772382B/zh active
- 2018-03-15 CA CA3056612A patent/CA3056612A1/en active Pending
- 2018-03-15 EA EA201992168A patent/EA201992168A1/ru unknown
- 2018-03-15 KR KR1020227043234A patent/KR20230003308A/ko not_active Ceased
- 2018-03-15 BR BR112019018966-1A patent/BR112019018966A2/pt not_active Application Discontinuation
-
2019
- 2019-09-04 IL IL26913219A patent/IL269132A/en unknown
- 2019-09-13 CL CL2019002629A patent/CL2019002629A1/es unknown
- 2019-09-25 ZA ZA2019/06326A patent/ZA201906326B/en unknown
- 2019-09-25 US US16/582,362 patent/US11179386B2/en active Active
- 2019-10-10 CO CONC2019/0011271A patent/CO2019011271A2/es unknown
-
2021
- 2021-10-21 US US17/507,037 patent/US20220040170A1/en active Pending
- 2021-11-30 US US17/537,663 patent/US20220088006A1/en not_active Abandoned
-
2022
- 2022-05-18 AU AU2022203369A patent/AU2022203369B2/en active Active
- 2022-11-04 JP JP2022177578A patent/JP2023010754A/ja active Pending
-
2024
- 2024-01-30 JP JP2024011974A patent/JP7631572B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7631572B2 (ja) | デューテトラベナジンの類似体、その調製及び使用 | |
| EA016904B1 (ru) | Новый холиновый сокристалл эпалрестата | |
| CN102458435A (zh) | 认知衰退的抑制剂 | |
| EP1935892B1 (en) | Glycyrrhetinic acid-30-amide derivatives and the uses thereof | |
| AU2013259779B2 (en) | N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide | |
| CN108727347A (zh) | 一种阿片样物质受体(mor)激动剂的晶型及其制备方法 | |
| CN100572374C (zh) | 葛根素衍生物及其医学用途 | |
| JP5986635B2 (ja) | ５，６，７，８−テトラヒドロ−６−［ｎ，ｎ−ビス［（２−チエニル）エチル］］アミノ−１−ナフトール、及びその作製方法、及びその使用 | |
| HK40018479A (en) | Analogs of deutetrabenazine, their preparation and use | |
| CN116554144B (en) | SJ series aryl aniline compound and preparation method and medical application thereof | |
| CN104650003A (zh) | 一种沃替西汀化合物 | |
| CN103421002A (zh) | 盐酸小檗碱晶d型物质及制备方法和其药物组合物与用途 | |
| BR122014004636B1 (pt) | Forma cristalina i de [cloridrato de 4-metilbenzoato de 4-[2-dimetilamino-1-(1-hidroxiciclohexil)etil]fenila], seu uso e seus métodos de preparação, bem como composição farmacêutica | |
| EA044519B1 (ru) | Способ получения готовой лекарственной формы деутетрабеназина, содержащая его композиция и способ лечения субъекта, страдающего гиперкинетическим двигательным расстройством | |
| CN107445872B (zh) | 一种具有潜在脑靶向性的化合物及其制备方法与应用 | |
| RU2783865C2 (ru) | Фармацевтические композиции | |
| TW202542164A (zh) | 治療過動性運動障礙之化合物 | |
| CN105524077A (zh) | 银杏内酯k晶k型及制备方法和其组合物与用途 | |
| CN105585576A (zh) | 银杏内酯k晶l型及制备方法和其组合物与用途 | |
| JPH05504765A (ja) | 神経学的疾患を治療するための４，４′―〔９ｈ―フルオレン―９―イリデンビス（メチレン）〕ビスピリミジン | |
| CN116396289A (zh) | 百香果吲哚类生物碱的制备方法、组合物及在制备治疗抗抑郁症的药物或保健产品中的应用 | |
| BR112017000351B1 (pt) | Anidro cristalino de metanossulfonato de 5-cloro-n-({(5s)-2-oxo-3-[4-(5,6-diidro-4h-[1,2,4] triazin-1-il)f enil]-1,3-oxazolidin-5-il}metil)tiofeno-2-carboxamida, composição farmacêutica compreendendo dito anidrido e uso terapêutico da mesma | |
| CN113968850A (zh) | 一种神经递质再摄取抑制剂的晶型及其制备方法和用途 | |
| CN101420947A (zh) | 用于非恢复性睡眠的α-2-δ配体 | |
| CN109535149A (zh) | 甲磺酸替扎尼定化合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |